Evergreen’s CEO, James Cook, emphasized the alignment of the companies’ missions, stating, “Lantheus’ industry expertise and financial strength will help us bring our innovations to a broad patient population faster and support our mission to improve options for cancer patients through theranostic radiopharmaceuticals.”
The deal is expected to close in the second half of 2025, subject to regulatory clearances and other customary conditions.
Legal Teams
The acquisition involved four prominent law firms:
Lantheus was advised by Cooley LLP (partners: Bill Roegge, Div Gupta, Geoffrey Spolyar) and Ropes & Gray LLP (partner: Zak Goodwin).
Evergreen was represented by Skadden Arps Slate Meagher & Flom LLP, with a team including partners Graham Robinson, Laura Knoll, Resa Schlossberg, Maria Raptis, Maya Florence, and Moshe Spinowitz.
Additional legal counsel for Evergreen was provided by Lowenstein Sandler LLP, though details of their team were not immediately available.
Industry Impact
This acquisition strengthens Lantheus’ position in the radiopharmaceutical market, enabling it to streamline production, accelerate development, and expand its reach.
